StreetInsider.com News Articles

Pelthos Therapeutics (PTHS) PT Lowered to $40 at Lake Street

Mon, 12 Oct 2026 09:16:54 -0400

Lake Street analyst Thomas Flaten lowered the price target on Pelthos Therapeutics (NYSE: PTHS) to $40.00 (from $50.00) while maintaining a Buy rating.

Pelthos expands Zelsuvmi formulary coverage to 127M lives

Tue, 06 Oct 2026 08:05:47 -0400

Pelthos Therapeutics Inc. (NYSE American: PTHS) announced new formulary agreements that expand coverage for its molluscum contagiosum treatment, ZELSUVMI (berdazimer) topical gel, 10.3%, to 127 million, or approximately 69%, of commercially covered lives.

The Durham, N.C.-based company signed an agreement with a major pharmacy benefit manager (PBM) that covers approximately 24 million lives, adding ZELSUVMI to its national formulary without requiring prior authorization, effective October 1, 2026. The PBM serves roughly one in three Americans and manages prescription drug benefits for employers, health plans, and government programs.

Pelthos also received a formulary update from a regional commercial health plan covering approximately 3

Pelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3%

Tue, 06 Oct 2026 08:00:00 -0400

Company secures new formulary coverage with a major Pharmacy Benefit Manager, reaching an additional 24 million covered lives

Pelthos gains enhanced commercial coverage through a regional commercial health plan representing approximately 3 million covered lives

Formulary coverage for ZELSUVMI increases to 127 million commercially covered lives

DURHAM, N.C., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos” or the “Company”), today announced that it signed an agreement with a major Pharmacy Benefit Manager (“PBM”)

Pelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3%

Tue, 06 Oct 2026 08:00:00 -0400

Company secures new formulary coverage with a major Pharmacy Benefit Manager, reaching an additional 24 million covered lives

Pelthos gains enhanced commercial coverage through a regional commercial health plan representing approximately 3 million covered lives

Formulary coverage for ZELSUVMI increases to 127 million commercially covered lives

Form ARS Pelthos Therapeutics For: Dec 31

Tue, 18 Aug 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260818/26945385.html

Form ARS Pelthos Therapeutics For: Dec 31

Tue, 18 Aug 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260818/26945385.html

Form DEFA14A Pelthos Therapeutics

Tue, 18 Aug 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260818/26945309.html

Form DEFA14A Pelthos Therapeutics

Tue, 18 Aug 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260818/26945309.html

Form DEF 14A Pelthos Therapeutics For: Sep 29

Tue, 18 Aug 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260818/26945241.html

Form DEF 14A Pelthos Therapeutics For: Sep 29

Tue, 18 Aug 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260818/26945241.html

Pelthos Therapeutics (PTHS) PT Lowered to $64 at Oppenheimer

Fri, 14 Aug 2026 08:34:01 -0400

Oppenheimer analyst Jeff Jones lowered the price target on Pelthos Therapeutics (NYSE: PTHS) to $64.00 (from $66.00) while maintaining a Outperform rating.

Form 10-Q Pelthos Therapeutics For: Jun 30

Thu, 13 Aug 2026 07:21:00 -0400

si-local-file:///var/storage/secattach/20260813/26916414.html

Form 10-Q Pelthos Therapeutics For: Jun 30

Thu, 13 Aug 2026 07:21:00 -0400

si-local-file:///var/storage/secattach/20260813/26916414.html

Pelthos Therapeutics Inc. (PTHS) Misses Q2 EPS by 611c

Thu, 13 Aug 2026 07:18:04 -0400

Pelthos Therapeutics Inc. (NYSE: PTHS) reported Q2 EPS of ($6.62), $6.11 worse than the analyst estimate of ($0.51). Revenue for the quarter came in at $15.6 million.

For earnings history and earnings-related data on Pelthos Therapeutics Inc. (PTHS) click here.

Form 8-K Pelthos Therapeutics For: Aug 13

Thu, 13 Aug 2026 07:16:00 -0400

si-local-file:///var/storage/secattach/20260813/26916389.html

Form 8-K Pelthos Therapeutics For: Aug 13

Thu, 13 Aug 2026 07:16:00 -0400

si-local-file:///var/storage/secattach/20260813/26916389.html

Pelthos Therapeutics Announces Second Quarter 2026 Financial Results

Thu, 13 Aug 2026 07:10:00 -0400

Zelsuvmi® net product revenue grew 45% to $15.4 million during the second quarter of 2026 from $10.7 million in the first quarter of 2026

11,925 Zelsuvmi units were dispensed by 4,571 unique prescribers during the second quarter of 2026, representing a 48% quarter-over-quarter increase in units dispensed

More than 25,000 patients have now been prescribed Zelsuvmi since it was commercially launched in July 2025

Management will host a conference call today, August 13, 2026, at 8:30 a.m. ET

DURHAM, N.C., Aug. 13,

Pelthos Therapeutics Announces Second Quarter 2026 Financial Results

Thu, 13 Aug 2026 07:10:00 -0400

Zelsuvmi® net product revenue grew 45% to $15.4 million during the second quarter of 2026 from $10.7 million in the first quarter of 2026

11,925 Zelsuvmi units were dispensed by 4,571 unique prescribers during the second quarter of 2026, representing a 48% quarter-over-quarter increase in units dispensed

More than 25,000 patients have now been prescribed Zelsuvmi since it was commercially launched in July 2025

Management will host a conference call today, August 13, 2026, at 8:30 a.m. ET

DURHAM, N.C., Aug. 13,

Pelthos Therapeutics Announces Second Quarter 2026 Financial Results

Thu, 13 Aug 2026 07:10:00 -0400

Zelsuvmi® net product revenue grew 45% to $15.4 million during the second quarter of 2026 from $10.7 million in the first quarter of 2026

11,925 Zelsuvmi units were dispensed by 4,571 unique prescribers during the second quarter of 2026, representing a 48% quarter-over-quarter increase in units dispensed

More than 25,000 patients have now been prescribed Zelsuvmi since it was commercially launched in July 2025

Management will host a conference call today, August 13, 2026, at 8:30 a.m. ET

DURHAM, N.C., Aug. 13,

Pelthos Therapeutics Announces Second Quarter 2026 Financial Results

Thu, 13 Aug 2026 07:10:00 -0400

Zelsuvmi® net product revenue grew 45% to $15.4 million during the second quarter of 2026 from $10.7 million in the first quarter of 2026

11,925 Zelsuvmi units were dispensed by 4,571 unique prescribers during the second quarter of 2026, representing a 48% quarter-over-quarter increase in units dispensed

More than 25,000 patients have now been prescribed Zelsuvmi since it was commercially launched in July 2025

Management will host a conference call today, August 13, 2026, at 8:30 a.m. ET

DURHAM, N.C., Aug. 13,

Form 10-Q/A Pelthos Therapeutics For: Mar 31

Thu, 13 Aug 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260813/26916311.html

Form 10-Q/A Pelthos Therapeutics For: Mar 31

Thu, 13 Aug 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260813/26916311.html

Form 8-K Pelthos Therapeutics For: Aug 12

Thu, 13 Aug 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260813/26916253.html

Form 8-K Pelthos Therapeutics For: Aug 12

Thu, 13 Aug 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260813/26916253.html

Form PRE 14A Pelthos Therapeutics For: Sep 29

Fri, 07 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260807/26892009.html